Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | IKBKB | O14920 | 3/20 | 0.42 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | USP2 | O75604 | 2/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CCR6 | P51684 | 1/20 | 0.40 |
| ▸ | PAK1 | Q13153 | 2/20 | 0.40 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10228636 | 0.94 | HTR6 (0.45) | TP53LMNAIKBKBMAPK8CYP1A2 | |
| SCHEMBL6128796 | 0.94 | HTR6 (0.45) | TP53LMNAIKBKBMAPK8CYP1A2 | |
| SCHEMBL18419022 | 0.89 | TP53 (0.54) | TP53LMNAALDH1A1TSHRL3MBTL1 | |
| SCHEMBL10228229 | 0.89 | L3MBTL1 (0.43) | TP53LMNAL3MBTL1HTR6CCR6 | |
| SCHEMBL6128887 | 0.88 | RPS6KB1 (0.44) | TP53LMNAL3MBTL1AURKARPS6KB1 | |
| SCHEMBL17545830 | 0.88 | RPS6KB1 (0.44) | TP53LMNAL3MBTL1AURKARPS6KB1 | |
| SCHEMBL31124371 | 0.88 | TP53 (0.43) | TP53LMNAL3MBTL1CCR6PAK1 | |
| SCHEMBL17545959 | 0.87 | TP53 (0.45) | TP53LMNAALDH1A1TSHRL3MBTL1 | |
| SCHEMBL17966303 | 0.84 | GRIN2B (0.38) | TP53LMNAIKBKBMAPK8L3MBTL1 | |
| SCHEMBL16764865 | 0.82 | TP53 (0.38) | TP53LMNAL3MBTL1HTR6CCR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10420768-B2 | Pyrrolopyrimidine derivatives as NR2B NMDA receptor antagonists | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2019-09-24 | — | — | US | disclosed |
| EP-3194403-B1 | PYRROLOPYRIMIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS | RUGEN HOLDINGS CAYMAN LTD (KY) | 2019-02-06 | — | — | EP | disclosed |
| US-20180303834-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2018-10-25 | — | — | US | disclosed |
| US-9968610-B2 | Pyrrolopyrimidine derivatives as NR2B NMDA receptor antagonists | RUGEN HOLDINGS (CAYMAN) LIMITED (US) | 2018-05-15 | — | — | US | disclosed |
| US-9968610-B2 | Pyrrolopyrimidine derivatives as NR2B NMDA receptor antagonists | RUGEN HOLDINGS (CAYMAN) LIMITED (US) | 2018-05-15 | — | — | US | disclosed |
| US-20170209449-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2017-07-27 | — | — | US | disclosed |
| US-20170209449-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2017-07-27 | — | — | US | disclosed |
| US-20170209449-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2017-07-27 | — | — | US | disclosed |
| US-9567341-B2 | Pyrrolopyrimidine derivatives as NR2B NMDA receptor antagonists | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2017-02-14 | — | — | US | disclosed |
| US-9567341-B2 | Pyrrolopyrimidine derivatives as NR2B NMDA receptor antagonists | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2017-02-14 | — | — | US | disclosed |
| US-9567341-B2 | Pyrrolopyrimidine derivatives as NR2B NMDA receptor antagonists | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2017-02-14 | — | — | US | disclosed |
| WO-2016044323-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2016-03-24 | — | — | WO | disclosed |
| US-20160075713-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2016-03-17 | — | — | US | disclosed |
| US-20160075713-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2016-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170209449-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS | GRIN1, GRIN2A, GRIN2B | TP53 3585/4885LMNA 4697/4885IKBKB 1515/4885 |
| US-10420768-B2 | Pyrrolopyrimidine derivatives as NR2B NMDA receptor antagonists | GRIN1, GRIN2A, GRIN2B | TP53 3585/4885LMNA 4697/4885IKBKB 1515/4885 |
| US-20160075713-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS | GRIN1, GRIN2A, GRIN2B | TP53 3585/4885LMNA 4697/4885IKBKB 1515/4885 |
| US-20180303834-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS | GRIN1, GRIN2A, GRIN2B | TP53 3585/4885LMNA 4697/4885IKBKB 1515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.